Nucleus Genomics Acquires Cambrean

I'm delighted to announce that Cambrean is now part of Nucleus Genomics.

Our mission has always been to help people better understand their health, and I'm grateful for the support of Cambrean users, who continue to shed light on the fact that we're merely scratching the surface when it comes to utilizing the health data we already have.

We built Cambrean from the ground up to focus on the relationships between your sleep, nutrition, workouts, and vitals. Since 2021, we have analyzed millions of datapoints across sleep, activities, recovery and nutrition to enable users to benefit from that data more efficiently. We spent thousands of hours submerged in research papers, design files, and code to rethink how we analyze health data.

But we can do better: Combining this data with your DNA gives you the most holistic picture of your health.

Joining Nucleus, which offers the deepest, most clinically rigorous genetic analysis on the U.S. market today, takes Cambrean’s vision to the next level. Together, we’re going to combine continuous health tracking with whole-genome sequencing for the very first time.

I will be joining Nucleus, working with their incredible team of engineers, designers and scientists to build the all-in-one health platform. Dr. Darren Bowles, Cambrean’s co-founder and chief medical officer, will join the Nucleus scientific advisory board, adding deep medical expertise to decades of combined experience across genomics, computational biology, and medicine. Lucas, our chief technical officer, will continue improving wearable technology in the health and fitness space.

I’m grateful for the continued support of investors and mentors, particularly Shane Curran — who bet on me first — along with Jack Pierse, Mario Götze, Nic Carter, Max Ament, and Dan Kiely, and others.

You can order Nucleus here, or keep up with me here.

— David (Co-founder & CEO)